VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

Stock Comparison

WuXi AppTec Co., Ltd. vs Amgen Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

WuXi AppTec Co., Ltd.

603259 · Shanghai Stock Exchange

Market cap (USD)$37.4B
Gross margin (TTM)49.2%
Operating margin (TTM)42.7%
Net margin (TTM)41.7%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryCN
Data as of2026-05-01
Moat score
72/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into WuXi AppTec Co., Ltd.'s moat claims, evidence, and risks.

View 603259 analysis

Amgen Inc.

AMGN · Nasdaq Stock Market

Market cap (USD)$181.9B
Gross margin (TTM)71.5%
Operating margin (TTM)31.6%
Net margin (TTM)21%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-22
Moat score
70/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Amgen Inc.'s moat claims, evidence, and risks.

View AMGN analysis

Comparison highlights

  • Moat score gap: WuXi AppTec Co., Ltd. leads (72 / 100 vs 70 / 100 for Amgen Inc.).
  • Segment focus: WuXi AppTec Co., Ltd. has 3 segments (84% in WuXi Chemistry); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
  • Moat breadth: WuXi AppTec Co., Ltd. has 5 moat types across 3 domains; Amgen Inc. has 5 across 3.

Primary market context

WuXi AppTec Co., Ltd.

WuXi Chemistry

Market

Global synthetic-molecule CRDMO services, including small-molecule discovery, process development, API manufacturing, peptides and oligonucleotides

Geography

Global, with major customer exposure to the United States, Europe and China

Customer

Large pharmaceutical companies, emerging biotechs and virtual pharma companies

Role

Integrated contract research, development and manufacturing partner across discovery, development and commercial manufacturing

Revenue share

84%

Amgen Inc.

Core Innovative Medicines

Market

Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)

Geography

Global

Customer

Payers, providers, and pharmacies

Role

Drug developer/manufacturer

Revenue share

80.1%

Side-by-side metrics

WuXi AppTec Co., Ltd.
Amgen Inc.
Ticker / Exchange
603259 - Shanghai Stock Exchange
AMGN - Nasdaq Stock Market
Market cap (USD)
$37.4B
$181.9B
Gross margin (TTM)
49.2%
71.5%
Operating margin (TTM)
42.7%
31.6%
Net margin (TTM)
41.7%
21%
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Drug Manufacturers - General
HQ country
CN
US
Primary segment
WuXi Chemistry
Core Innovative Medicines
Market structure
Competitive
Competitive
Market share
6%-9% (implied)
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
72 / 100
70 / 100
Moat domains
Supply, Demand, Legal
Legal, Supply, Demand
Last update
2026-05-01
2025-12-22

Moat coverage

Shared moat types

No overlap yet.

WuXi AppTec Co., Ltd. strengths

Scope EconomiesDesign In QualificationCapacity MoatCompliance AdvantageOperational Excellence

Amgen Inc. strengths

IP Choke PointRegulated Standards PipeCapex Knowhow ScaleBrand TrustLearning Curve Yield

Segment mix

WuXi AppTec Co., Ltd. segments

Full profile >

WuXi Chemistry

Competitive

84%

WuXi Testing

Competitive

9.3%

WuXi Biology

Competitive

6.2%

Amgen Inc. segments

Full profile >

Core Innovative Medicines

Competitive

80.1%

Rare Disease Portfolio (Horizon + others)

Quasi-Monopoly

13.3%

Biosimilars

Oligopoly

6.6%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.